Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
| − | == | + | ==Profile Documents== |
| − | *[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx| | + | *[[Media:QIBA_Profile_MSK-Cartilage-Stage2_Profile.pdf|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile]] |
| + | *[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile]] | ||
==Statistical Reference Documents== | ==Statistical Reference Documents== | ||
Revision as of 17:19, 18 February 2022
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Profile Documents
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile